Dr. Carine E. Bou-Abboud Matta, MD

Dr. Bou-Abboud Matta practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Bou-Abboud Matta's NPI, 1790028389, was assigned on April 1, 2013. Dr. Bou-Abboud Matta holds Ohio license 25.127586.

Dr. Bou-Abboud Matta's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Bou-Abboud Matta's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Bou-Abboud Matta is also affiliated with University Hospitals Ahuja Medical Center. The medical group on file is University Hospitals Medical Practices.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bou-Abboud Matta practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Bou-Abboud Matta's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Bou-Abboud Matta is licensed in Ohio.

CMS data shows 189 Medicare services from Dr. Bou-Abboud Matta across 6 procedure codes in 2024, for 135 Medicare patients. Medicare paid $14,276 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 135 Medicare patients who saw Dr. Bou-Abboud Matta in 2024. The largest group is 65 to 74, with 64 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bou-Abboud Matta's median patient age at 68, with 71% women.

In 2024, Dr. Bou-Abboud Matta wrote 145 Medicare Part D claims for 67 patients. 89% of them were for generic drugs. CMS names the drug for 104 of them, across 5 drugs with 11 or more claims each, at $6,610 in total drug cost. In 2023, CMS named 118 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Bou-Abboud Matta for performance year 2024, reported as part of a group. Dr. Bou-Abboud Matta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 19 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Bou-Abboud Matta, more than 49% of the clinicians it reports for that procedure.

CMS Open Payments shows 75 general payments to Dr. Bou-Abboud Matta from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $556.